UNSPSC 51144403: Rimonabant

This classification denotes an anxiolytic with the molecular formula C22H21Cl3N4O.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier HL0V2LQZ09, chemically known as 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-n-1-piperidinyl-1h-pyrazole-3-carboxamide monohydrochloride, but more generally known as rimonabant hydrochloride, which bears US NIH Compound Identifier 104849.

European Medicines Agency schedules rimonabant hydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB21719. Most nations, for tariff purposes, schedule rimonabant hydrochloride under HS 29333999. SMILES: CC1C(N(NC1C(=O)NN2CCCCC2)C3CCC(CC3CL)CL)C4CCC(CC4)CL.CL.

UNSPSC 51144403 Rimonabant is a Commodity code that maps to pharmaceutical procurement, but recent state and local opportunities tagged under this code do not focus on rimonabant itself. Instead, they reflect broader pharmaceutical and health-system supply acquisition: naloxone and drug deactivation systems for public-health emergency response, direct-to-manufacturer pharmacy benefit programs, and generic multi-source pharmaceuticals distributed through wholesaler networks. State and local governments use this code tier to procure pharmaceutical products, medical supplies, and related services that support community health infrastructure, corrections systems, public-health departments, and employee benefit programs. Issuing bodies span county health departments, state HHS agencies, and multi-state cooperative purchasing organizations. Seminole County, Florida and the Minnesota Department of Administration's Office of State Procurement have issued recent solicitations; the Texas Health and Human Services Commission issued an RFI to explore direct-to-manufacturer contracting models for pharmacy benefit management.

Geographic activity centers on Florida, Minnesota, and Texas. Seminole County's IFB 60459723LAS (posted June 30, 2026, response due July 26, 2023) seeks 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly delivery to the Seminole County Community Health Building in Sanford, Florida; the contract carries a two-year initial term with a one-year renewal option and requires e-Verify compliance and drug-free workplace certification. The Minnesota Multistate Cooperative Purchasing Alliance issued RFP S1070000015802 (posted January 20, 2026, response due March 26, 2026) to establish multiple contracts for generic pharmaceuticals and OTC products distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson, with evaluations weighted 75 percent on price competitiveness, cGMP and Drug Supply Chain Security Act compliance required, and a two-year initial term. The Texas HHS Commission's RFI HHS0017013 (posted April 3, 2026) explores vendor capacity for direct-to-manufacturer pharmacy programs outside traditional PBM and GPO arrangements, signaling state-level interest in alternative pharmaceutical-supply models for self-insured health plans and government employee benefit programs.